Itraconazole and hydroxyitraconazole concentrations combined should not exceed 10 µg/mL. Adverse effects may include nausea, vomiting and rash.
Compliance Statement B
: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.